Semaglutide (Glp-1 Receptor Agonist) Injectable Solution Suppliers & Bulk Manufacturers
Available Forms: Injectable solution (prefilled pen)
Available Strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 2 mg/0.5 mL
Reference Brands: Ozempic(EU & US)
Category:
Diabetes
Semaglutide is a GLP-1 receptor agonist that mimics the action of incretin hormones to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, helping control blood sugar. It is used for type 2 diabetes management and chronic weight control in obese or overweight adults, improving glycemic levels and promoting satiety.
Semaglutide (GLP-1 receptor agonist) Injectable solution is available in Injectable solution (prefilled pen)
and strengths such as 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 2 mg/0.5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Semaglutide (GLP-1 receptor agonist) Injectable solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Semaglutide (GLP-1 receptor agonist) Injectable solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Semaglutide, a GLP-1 receptor agonist available as an injectable solution (e.g., Ozempic, Wegovy), is FDA-approved in the USA for type 2 diabetes and chronic weight management in adults. It requires Boxed Warnings for potential thyroid C-cell tumors and must meet GMP, labeling, and post-marketing surveillance standards. In the EU, semaglutide is centrally approved by the EMA for the same indications, with stringent requirements for Risk Management Plans (RMPs) and pharmacovigilance reporting. Ongoing clinical safety and batch quality oversight are essential in both markets. Explore compliant supply options at Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing